Sun Pharma Is Well Poised To Sustain Growth In Focus Segments, Says Motilal Oswal Maintaining 'Buy'

Despite a large base (Rs 175 billion sales over 12 months ending Jun’25), Sun Pharma intends to grow better than the industry going forward as well.

(Photo: Sun Pharmaceutical Industries/Facebook)

Sun Pharma aims to sustain its outperformance in the domestic formulation segment through increased doctor engagement, new launches, addition of field force and strengthening the brand recall of its existing products.

To continue reading this story You must be an existing Premium User Already a Premium User? Sign In